Skip to main content

Table 1 Patient characteristics, asthma-related quality of life (AQLQ), atopic dermatitis related quality of life (DLQI), and asthma-related treatment at baseline and after 6 and 12 months omalizumab therapy

From: Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy

  Asthma Asthma + atopic dermatitis P value
n 13 9  
Age (years) 47.5 ± 14.8 38.1 ± 11.3 0.127
Sex /female) 10/13 77% 6/9 67% 0.394
IgE 212 ± 224 3528 ± 2723 < 0.001
FEV1 71.5 ± 10,7 76.2 ± 7,4 0.350
Weight in kg 82.3 ± 22.0 76.3 ± 16.1 0.472
Omalizumab dosage    
(mg/2 weeks) 213 ± 86 233 ± 109 0.654
OCS baseline 12/13 7/9 0.394
OCS 6 month 4/13 0/9 0.003
OCS 12 month 4/13 0/9 0.003
AQlQ baseline 102 ± 40 143 ± 44 0.041
AQlQ 6 month 148 ± 48 175 ± 40 0.041
AQlQ 12 month 152 ± 45 170 ± 42 0.04
DlQI baseline   19 ± 10  
DlQI 6 month   7 ± 8  
DlQI 12 moth   6 ± 6  
  1. OCS, oral corticosteroids, ICS, inhaled corticosteroids.